Safety and Efficacy of XELOX Combined With Sintilimab and Lenvatinib in Advanced AFP-positive Gastric Cancer Patients

NCT06383559 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

39

Enrollment

OTHER

Sponsor class

Conditions

Gastric Cancer

Interventions

DRUG: Lenvatinib and Sintilimab

Sponsor

Tianjin Medical University Cancer Institute and Hospital